Takeda Pharmaceutical (TSE:4502) Wins MIMRYLO Approval, Is The Stock Still Trading At A Discount?

Takeda Pharmaceutical (TSE:4502) is back in focus after two recent announcements. The stock is reacting to U.S. approval of MIMRYLO and an expanded AI collaboration with Weave Bio that targets global regulatory workflows.

Even after a 2.7% pullback in the latest session to ¥5,748, Takeda Pharmaceutical’s 30-day share price return of 9.1% and 90-day gain of 16.7% suggest momentum has been building. A 1-year total shareholder return of 30.8% points to sustained interest as new product approvals and AI initiatives influence how investors view the company’s growth potential and risk profile.

Surf 26 high quality undervalued stocks hand-picked for investors following Takeda Pharmaceutical’s momentum in new treatments and AI-enabled drug development.

Given Takeda Pharmaceutical’s recent run and current price of ¥5,748, the gap between where the stock trades and where various fair value estimates cluster is hard to ignore. How wide is that spread in practical terms for investors?

Most Popular Narrative: 11.1% Undervalued

At a last close of ¥5,748, the most followed narrative puts Takeda Pharmaceutical’s fair value at ¥6,468. That gap rests on specific pipeline and growth assumptions that sit well beyond the latest MIMRYLO and AI headlines.

The anticipated moderation and eventual stabilization of VYVANSE generic erosion after FY2025 will remove a major headwind for revenues, allowing Takeda’s core growth and launch products to drive top-line and earnings recovery going forward.

Rapid progress and positive late-stage data from Takeda’s innovative pipeline, especially in high-need therapeutic areas like rare diseases (orexin agonists for narcolepsy, rusfertide for polycythemia vera), set the stage for multiple high-value product launches, which can catalyze multi-year revenue and margin expansion. Read the complete narrative.

Want to see what is behind that valuation gap for Takeda Pharmaceutical? The narrative leans on a specific blend of revenue growth, margin repair and a future earnings multiple that stretches well beyond today’s loss making starting point. Curious which assumptions have to align for that fair value to hold up over time? The full narrative lays out the numbers in detail.

Result: Fair Value of ¥6,468.94 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the bullish Takeda Pharmaceutical story still faces pressure from generic competition around key drugs, as well as potential setbacks or delays in late stage pipeline programs.

Find out about the key risks to this Takeda Pharmaceutical narrative.

Another View on Takeda Pharmaceutical’s Valuation

The analyst narrative points to Takeda Pharmaceutical trading below a fair value of ¥6,468, yet the SWS DCF model suggests an even larger gap. At a price of ¥5,748 and an estimated future cash flow value of ¥14,378.70, the stock screens as significantly undervalued. Which set of assumptions appears more realistic to you?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With sentiment split between opportunity and caution around Takeda Pharmaceutical, it makes sense to move quickly and test the numbers for yourself. To weigh both sides of the story in one place, review the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Takeda Pharmaceutical?

If you only stop at Takeda Pharmaceutical, you could miss other opportunities that fit your style. Use the Simply Wall St screener to quickly surface fresh ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com